Pathophysiology and management of sensitive skin: position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI)

The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology Vol. 34; no. 2; pp. 222 - 229
Main Authors: Misery, L., Weisshaar, E., Brenaut, E., Evers, A.W.M., Huet, F., Ständer, S., Reich, A., Berardesca, E., Serra‐Baldrich, E., Wallengren, J., Linder, D., Fluhr, J.W., Szepietowski, J.C., Maibach, H., Honari, Golara, Le Gall‐Ianotto, Christelle, Takamori, Kenji, Richters, Renée
Format: Journal Article
Language:English
Published: England Wiley 01-02-2020
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors. Avoidance of possible triggering factors and the use of well‐tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin.
Bibliography:Conflicts of interest
None.
LM is an consultant of Beiersdorf, Bioderma, Clarins, Expanscience, Johnson & Johnson, Nestlé Skin Health, Pierre Fabre, La Roche‐Posay, Solabia and Uriage; EW, AWME, SS, EB, ESB, JW, DL, JCS and HM declared none; EB is an consultant of Bioderma, Clarins, Nestlé Skin Health and Pierre Fabre; FH is an consultant of Beiersdorf, Clarins and Pierre Fabre; AR is an consultant of Bioderma, Galderma and Pierre Fabre; JWF is an consultant of Bioderma, Nestlé Skin Health, Sebapharma and Pierre Fabre.
Funding source
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.16000